Various types of biomaterials have been widely used to
treat complex
bone defects. However, potential infection risks and inappropriate
host immune responses induced by biomaterials can adversely affect
the final bone repair outcome. Therefore, the development of novel
bone biomaterials with antibacterial and immunomodulatory capabilities
is conducive to achieving a good interaction between the host and
material, thereby creating a local microenvironment favorable for
osteogenesis and ultimately accelerating bone regeneration. In this
study, we fabricated a porcine small intestinal submucosa (SIS) hydrogel
containing LL37 peptides and polylactic-glycolic acid (PLGA) microspheres
encapsulated with WP9QY(W9) peptide (LL37-W9/PLGA-SIS), which can
fill irregular bone defects and exhibits excellent mechanical properties.
In vitro experiments showed that the microsphere–gel composite
system had sequential drug release characteristics. The LL37 peptide
released first had good antibacterial performance and BMSC recruitment
ability, which could prevent infection at an early stage and increase
the number of BMSCs at the injured site. In addition, it also has
immunomodulatory properties, showing both pro-inflammatory and anti-inflammatory
activities, but its early pro-inflammatory properties are more inclined
to activate the M1 phenotype of macrophages. Moreover, the subsequently
released W9 peptide not only reduced the expression of pro-inflammatory
genes to alleviate inflammation and induced more macrophages to convert
to M2 phenotypes but also promoted the osteogenic differentiation
of BMSCs. This finely regulated immune response is considered to be
more closely related to the physiological bone healing process. When
studying the interaction between macrophages and BMSCs mediated by
the material, it was found that the immunomodulatory and osteogenic
effects were enhanced. In vivo experiments, we constructed rat skull
defect models, which further proved that LL37-W9/PLGA-SIS gel can
properly regulate the immune response, and has a good ability to promote
osteogenesis in situ. In conclusion, the LL37-W9/PLGA-SIS hydrogel
has great application prospects in immune regulation and bone therapy.